Peer-Reviewed Publications

      Lung inflammation in rats following subchronic exposure to cigarette mainstream smoke

      Friedrichs, B.; van Miert, E.; Vanscheeuwijck, P.
      Published
      Mar 31, 2006
      DOI
      10.1080/01902140600817457
      PMID
      16908445
      Link to publication
      Topic
      Summary

      Female Sprague-Dawley rats were exposed to mainstream smoke from standard reference cigarettes and a nontobacco cellulose cigarette for 35 days. Whole smoke and smoke fractions were investigated. Lung inflammation was evaluated by differentiation of bronchoalveolar lavage cells and lymphocytes in thoracic lymph nodes. Histopathological changes in the nose and larynx were assessed. Results showed that the particulate phase of cigarette mainstream smoke is mostly responsible for inflammation in the lung (neutrophil increase up to 240-fold) and hyperplastic and metaplastic epithelial changes in the larynx, whereas irritative volatile constituents in the gas phase are mostly responsible for changes in the nose.

      Related Publications

      Key Challenges and Recommendations for In Vitro Testing of Tobacco Products for Regulatory Applications: Consideration of Test Materials and Exposure Parameters

      Pre-clinical Toxicology

      Quantification and mapping of alkylation in the human genome reveal single nucleotide resolution precursors of mutational signatures

      Pre-clinical Toxicology

      An in vitro evaluation of e-vapor products: The contributions of chemical adulteration, concentration, and device power

      Pre-clinical Toxicology

      Tobacco heating system has less impact on bone metabolism than cigarette smoke

      Pre-clinical Toxicology

      Novel α7 nicotinic acetylcholine receptor modulators as potential antitussive agents

      Pre-clinical Toxicology

      Differentiating the neuropharmacological properties of nicotinic acetylcholine receptor-activating alkaloids

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.